Two new medications are now available to treat metastatic or locally advanced Basal Cell Carcinoma. Erivedge (Vismodegib) and Odomzo (Sonidegib) have been approved by the F.D.A. and have similar mechanisms of action.
Oral medication used to treat metastatic B.C.C., or locally-advanced B.C.C.
that has recurred following surgery or in patients who are not candidates
for surgery and are not candidates for radiation therapy
Dosage: 150 mg p.o. daily for Erivedge and 200 mg. p.o. daily for Odomzo
Cost: $11,268.79 for a 28 day
treatment for Erivedge
Mechanisms of action: B.C.C. may be associated with mutations in Hedgehog pathway components. Hedgehog regulates cell growth and differentiation in embryogenesis; while generally not active in adult tissue, Hedgehog mutations associated with B.C.C. can activate the pathway resulting in unrestricted proliferation of skin basal cells. Erivedge is a selective Hedgehog pathway inhibitor.
Adverse Reactions:
Teratogenic effects
Fatigue
Alopecia
Muscle Spasms
Gastrointestinal
Mechanisms of action: B.C.C. may be associated with mutations in Hedgehog pathway components. Hedgehog regulates cell growth and differentiation in embryogenesis; while generally not active in adult tissue, Hedgehog mutations associated with B.C.C. can activate the pathway resulting in unrestricted proliferation of skin basal cells. Erivedge is a selective Hedgehog pathway inhibitor.
Adverse Reactions:
Teratogenic effects
Fatigue
Alopecia
Muscle Spasms
Gastrointestinal
